|
Interesting senerio.
Our northern neighbors can supply inexpensive nameless brands which would cover 80-90% of the common usage needed here, and be affordable for the common joe.
It wouldn't be a domestic product though.
Meanwhile, the U.S. pharmas are intent on spending gobs on advertising(up to five times R&D I think), and/or repackaging/repatenting the same drugs to sell them at outrageous cost to people who simply can't afford it.
Big pharma-1, citizen-0.
There is a parallel to the domestic auto industry as well. They may have had a captive audience historically, but it is now broke.
Either they'll be part of the solution, or part of the problem.
|